J&J Outlines Pricing Transparency Plan, Will Others Follow?

CEO Gorsky describes J&J’s approach to drug pricing and pledges to provide more detail in an annual transparency report. Investor pressure regarding the pricing debate continued during the Novartis earnings call. Value arguments expected to dominate pharma’s message.

Johnson & Johnson laid down a gauntlet during its earnings call Jan. 24 with a pledge to produce an annual report providing pricing transparency for its drugs, providing the latest sign from the biopharma industry that it recognizes business as usual can't continue in the US.

With President Donald Trump taking fire at pharma, several US policy debates are sure to be prominent features as industry...